TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
TCX201: A Therapeutic Approach
We're working to file our IND sometime this year. Right now we're targeting the middle of the year. I will say that this is a very complex patient population. We talk about roughly 3000 patients and allogeneic stem cell transplants and, and AML,. So what does it look like for a patient? You know, the patients are still going to have to go through transplant. The idea is that that experience shouldn't change too much. It's just a question in this sort of therapeutic approach. If we can run a study and create a therapy that minimizes the need for immunosuppression later, it could make the difference between life or death with TCX201.
Transcript
Play full episode
